Table I.
Clinical and laboratory features of MDS-F patients by TP53 expression status.
| Variable | MDS-F with TP53neg-low | MDS-F with TP53high | p value | |
|---|---|---|---|---|
| n=56 | n=11 | |||
| Age at diagnosis, median years (range) | 65.3 (27.3–91.3) | 60.4 (18.1–76.3) | 0.4145 | |
| Sex | ||||
| Male | 35 (62.5) | 7 (63.6) | 1.0000 | |
| Female | 21 (37.5) | 4 (36.4) | ||
| Transfusion dependence | 36 (64.3) | 3 (27.3) | 0.0417 | |
| Palpable organomegaly | 18 (32.1) | 1 (9.1) | 0.1592 | |
| Complete blood count | ||||
| ANC (× 109/l), median (range) | 1.74 (0.1–7.8) | 0.85 (0.12–5.6) | 0.0985 | |
| Haemoglobin (g/l), median (range) | 96 (62–137) | 93 (76–116) | 0.4641 | |
| Platelet count (× 109/l), median (range) | 57 (2–409) | 33 (7–236) | 0.1460 | |
| Circulating blast %, median (range) | 0 (0–9) | 0 (0–6) | 0.2767 | |
| Cytogenetics categories* | n=55 | |||
| Diploid | 18 (32.7) | 2 (18.2) | 0.4816 | |
| Del 20q | 4 (7.3) | 2 (18.2) | 0.2598 | |
| −5/ del 5q | 7 (12.7) | 7 (63.6) | 0.0009 | |
| −7/ del 7q | 6 (10.9) | 5 (45.5) | 0.0141 | |
| −17/ del 17p | 6 (10.9) | 3 (27.3) | 0.1648 | |
| +8 | 9 (16.3) | 1 (9.1) | 1.0000 | |
| Complex karyotype* | 8 (14.5) | 8 (72.7) | 0.0002 | |
| IPSS-R “poor”/“very poor” cytogenetics | 13 (23.6) | 8 (72.7) | 0.0030 | |
| IPSS-R category | n=52 | 0.0090† | ||
| Very low | 2 (3.8) | 0 | ||
| Low | 15 (28.8) | 0 | ||
| Intermediate | 16 (30.8) | 2 (18.2) | ||
| High | 6 (11.5) | 2 (18.2) | ||
| Very high | 13 (25) | 7 (63.6) | ||
Abbreviations: MDS-F: myelodysplastic syndrome with fibrosis; ANC: absolute neutrophil count; IPSS-R: Revised International Prognostic Scoring System for Myelodysplastic Syndromes.
*
Defined as >3 karyotypic abnormalities.
†
“Very low” and “low-risk” vs. “high and very high-risk” groups.